Search Results

You are looking at 131 - 140 of 178 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

a clinical relapse is 2 to 6 months. A lack of consensus exists regarding the timing of recurrence therapy for patients who have undergone previous chemotherapy. Because tamoxifen and other hormonally active agents have a defined response rate in

Full access

Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen

erythropoietic stimulating agents (ESAs). Exogenous hormonal compounds, such as selective estrogen receptor modulators (eg, tamoxifen, raloxifene for breast cancer) can lead to increased VTE risk. 92 – 96 Diethylstilbestrol phosphate used in combination with

Full access

Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead, and Hema Sundar

history of breast cancer, although for women treated with tamoxifen, levonorgestrel-containing intrauterine system (IUS) may be preferable because it has been shown to reduce tamoxifen-induced endometrial changes without increasing the risk of breast

Full access

Scott V. Bratman, Kathleen C. Horst, Robert W. Carlson, and Daniel S. Kapp

treatment break was required to allow for healing after the patient developed moist desquamation on the chest wall. Tamoxifen was initiated after radiotherapy and continues at the time of writing. 7 At 57 months after surgery, the patient has remained

Full access

Lillie D. Shockney

menopausal side effects caused by hormonal therapy used to prevent recurrence. I had a patient on tamoxifen who informed me that she felt much better after she had seen her gynecologist and received hormone replacement therapy (a class of drugs directly

Full access

Soft Tissue Sarcoma, Version 2.2012

Featured Updates to the NCCN Guidelines

Margaret von Mehren, Robert S. Benjamin, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo Gonzalez, Martin J. Heslin, John M. Kane III, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, Benjamin Paz, John D. Pfeifer, Raphael E. Pollock, R. Lor Randall, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Sridhar Shankar, Brian A. Van Tine, Jeffrey Wayne, Hema Sundar, and Nicole R. McMillian

). Other systemic therapy agents recommended in the guidelines include nonsteroidal anti-inflammatory drugs (sulindac or celecoxib), hormonal or biologic agents (tamoxifen, toremifene, low-dose interferon, or imatinib), and chemotherapy (methotrexate and

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

. Case 1 A 66-year-old Ashkenazi Jewish woman with a past medical history of early-stage invasive ductal carcinoma of the left breast, treated definitively with surgery and adjuvant tamoxifen therapy, presented after a routine colonoscopy revealed a 1

Full access

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

tamoxifen. All 3 patients had splenomegaly. The WBC count at presentation was 143,000/μL (66% blasts; 5% basophils) in the first patient ( Figure 1 ); 159,000/μL (36% blasts; 0%-2% basophils) in the second patient; and 96,900/μL (12% blasts; 1% basophils) in

Full access

Jesse D. Troy, Carlos M. de Castro, Mary Ruth Pupa, Greg P. Samsa, Amy P. Abernethy, and Thomas W. LeBlanc

.org . 3. Zabora J BrintzenhofeSzoc K Curbow B . The prevalence of psychological distress by cancer site . Psychooncology 2001 ; 10 : 19 – 28 . 4. Partridge AH Wang PS Winer EP Avorn J . Nonadherence to adjuvant tamoxifen therapy in

Full access

Tilmann Bochtler, Volker Endris, Anna Reiling, Jonas Leichsenring, Michal R. Schweiger, Sebastian Klein, Fabian Stögbauer, Benjamin Goeppert, Peter Schirmacher, Alwin Krämer, and Albrecht Stenzinger

hormone receptor–positive (estrogen receptor [ER], 12/12; progesterone receptor [PR], 8/12; HER2/neu, 1+) ductal adenocarcinoma of luminal type B, which was treated with surgical resection and subsequent adjuvant tamoxifen, which is still ongoing at time